Latest News

Cervical cancer is one of the most preventable and treatable forms of cancer1, yet over a quarter of a million women die from the disease…

Cervical cancer is the fourth most common cancer in women, with more than half a million women diagnosed with the disease in 20181. In low-…

TruScreen’s cervical cancer screening device demonstrates improved sensitivity and specificity targeting pre-cancerous and cancerous cervical cells

Dr. Carolina Velasquez traveled to Vietnam to conduct clinical training and launch the TruScreen Pilot Study, being conducted out of Hanoi Gynaecology and Obstetrics Hospital.…

TruScreen is pleased to provide a copy of its July 2019 Stakeholders Newsletter, providing an update on TruScreen’s performance and highlights key initiatives underway.

Joint publication that Unitaid has released with the World Health Organisation and the Clinton Health Access Initiative featuring TruScreen as the only Electro-optical Cervical Cancer…

Stockhead spoke to TruScreen CEO Martin Dillion at the Coffee Microcaps Conference in Sydney earlier this month.

TruScreen Limited (NZX: TRU) has been picked by Foster Stockbroking as a Top 5 Prospect for 2019 in the NZ Heral, 26 December 2018